In a new report, Credit Suisse analyst Kennen MacKay discusses the firm’s top biotech stock picks. According to MacKay, it’s important for investors to remain selective at the biotech sector undergoes a market correction.
Credit Suisse focused on four themes when identifying top biotech picks:
1. Potential near-term positive clinical catalysts
2. Potential near-term product launches
3. Solid management teams
4. Solid biology supporting underlying technology
Overall, the firm sees the pullback in small and mid-cap biotech names over the past year as a buying opportunity, but headwinds also remain in 2016.
“We favor companies with novel/unique biotechnology supported by strong underlying biology supporting their drug target, mechanism, and targeted indication,” MacKay explained.
Related Link: OECD Economist: We're In 'Epic' Situation Worse Than 2007
Credit Suisse’s top three Out Perform picks are Medivation Inc MDVN, Agios Pharmaceuticals Inc AGIO, and Ultragenyx Pharmaceutical Inc RARE.
In addition, the firm has a Neutral rating on FibroGen Inc FGEN and Akebia Therapeutics Inc AKBA and an Under Perform rating on OvaScience Inc OVAS.
Disclosure: the author holds no position in the stocks mentioned.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
